Published in Mol Cell Biol on February 27, 2012
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature (2014) 5.19
JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers. Cancer Res (2016) 0.88
Histone demethylases in chromatin biology and beyond. EMBO Rep (2015) 0.81
HMGB1 promotes HCC progression partly by downregulating p21 via ERK/c-Myc pathway and upregulating MMP-2. Tumour Biol (2015) 0.79
A chromatin activity-based chemoproteomic approach reveals a transcriptional repressome for gene-specific silencing. Nat Commun (2014) 0.78
The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells. Oncoimmunology (2016) 0.78
Processing Oscillatory Signals by Incoherent Feedforward Loops. PLoS Comput Biol (2016) 0.76
TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer. Clin Cancer Res (2016) 0.76
TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation. Oncogene (2016) 0.76
Original Research: miR-194 inhibits proliferation and invasion and promotes apoptosis by targeting KDM5B in esophageal squamous cell carcinoma cells. Exp Biol Med (Maywood) (2016) 0.75
Overexpression of JARID1B promotes differentiation via SHIP1/AKT signaling in human hypopharyngeal squamous cell carcinoma. Cell Death Dis (2016) 0.75
Molecular mechanisms of OLIG2 transcription factor in brain cancer. Oncotarget (2016) 0.75
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer (2009) 9.21
Synthetic peptides as nuclear localization signals. Nature (1986) 5.35
Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature (2002) 5.25
Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res (2005) 4.60
Quantitative interaction proteomics and genome-wide profiling of epigenetic histone marks and their readers. Cell (2010) 4.31
Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Curr Opin Cell Biol (2008) 4.25
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell (2007) 3.68
Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci U S A (2001) 3.02
Cardiac malformations, adrenal agenesis, neural crest defects and exencephaly in mice lacking Cited2, a new Tfap2 co-activator. Nat Genet (2001) 2.60
The Trithorax group protein Lid is a trimethyl histone H3K4 demethylase required for dMyc-induced cell growth. Genes Dev (2007) 2.57
The AP-2 family of transcription factors. Genome Biol (2005) 2.46
JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci U S A (2007) 2.45
MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci U S A (2010) 2.21
A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer. J Biol Chem (1999) 2.09
PARP-1 regulates chromatin structure and transcription through a KDM5B-dependent pathway. Mol Cell (2010) 2.06
A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene (1996) 2.00
Mechanism of transcriptional activation by the Myc oncoproteins. Semin Cancer Biol (2006) 1.91
AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat Genet (1997) 1.85
Physical and functional interactions among AP-2 transcription factors, p300/CREB-binding protein, and CITED2. J Biol Chem (2003) 1.65
Mutations in TFAP2B cause Char syndrome, a familial form of patent ductus arteriosus. Nat Genet (2000) 1.62
Functional analysis of the transcription repressor PLU-1/JARID1B. Mol Cell Biol (2007) 1.57
AP-2γ regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription. EMBO J (2011) 1.49
Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J Pathol (1999) 1.47
Histone demethylase KDM5A is an integral part of the core Notch-RBP-J repressor complex. Genes Dev (2010) 1.44
Activator protein-2 in carcinogenesis with a special reference to breast cancer--a mini review. Int J Cancer (2007) 1.42
Transcription factor AP-2 interacts with the SUMO-conjugating enzyme UBC9 and is sumolated in vivo. J Biol Chem (2002) 1.36
Human CREB-binding protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2. J Biol Chem (2001) 1.35
Transcriptional repression: the dark side of myc. Genes Cancer (2010) 1.34
Essential functions of the histone demethylase lid. PLoS Genet (2010) 1.34
Breast cancer associated transcriptional repressor PLU-1/JARID1B interacts directly with histone deacetylases. Int J Cancer (2007) 1.30
The histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. Gastroenterology (2009) 1.29
The ARID domain of the H3K4 demethylase RBP2 binds to a DNA CCGCCC motif. Nat Struct Mol Biol (2008) 1.28
Wwox and Ap2gamma expression levels predict tamoxifen response. Clin Cancer Res (2007) 1.22
c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J Biol Chem (2005) 1.22
Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. J Pathol (2009) 1.12
AP-2gamma promotes proliferation in breast tumour cells by direct repression of the CDKN1A gene. EMBO J (2009) 0.97
Selective targeting of histone methylation. Cell Cycle (2011) 0.92
Dual association by TFAP2A during activation of the p21cip/CDKN1A promoter. Cell Cycle (2010) 0.86
Alternative TFAP2A isoforms have distinct activities in breast cancer. Breast Cancer Res (2011) 0.85
Confirmation of TFAP2A gene involvement in branchio-oculo-facial syndrome (BOFS) and report of temporal bone anomalies. Am J Med Genet A (2009) 0.84
Targeting of SWI/SNF chromatin remodelling complexes to estrogen-responsive genes. EMBO J (2002) 2.02
Physical and functional interactions among AP-2 transcription factors, p300/CREB-binding protein, and CITED2. J Biol Chem (2003) 1.65
PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/testis antigen? Int J Cancer (2002) 1.39
Transcription factor AP-2 interacts with the SUMO-conjugating enzyme UBC9 and is sumolated in vivo. J Biol Chem (2002) 1.36
Human CREB-binding protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2. J Biol Chem (2001) 1.35
PLU-1/JARID1B/KDM5B is required for embryonic survival and contributes to cell proliferation in the mammary gland and in ER+ breast cancer cells. Int J Oncol (2011) 1.31
Analysis of SOCS-3 promoter responses to interferon gamma. J Biol Chem (2004) 1.08
FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1alpha. Oncogene (2002) 1.03
Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors. Genes Chromosomes Cancer (2008) 0.99
Interleukin-10 and cAMP-elevating agents cooperate to induce suppressor of cytokine signaling-3 via a protein kinase A-independent signal. Eur Cytokine Netw (2002) 0.98
AP-2gamma promotes proliferation in breast tumour cells by direct repression of the CDKN1A gene. EMBO J (2009) 0.97
Interaction and functional interference of glucocorticoid receptor and SOCS1. J Biol Chem (2008) 0.92
Activator protein-2gamma (AP-2gamma) expression is specifically induced by oestrogens through binding of the oestrogen receptor to a canonical element within the 5'-untranslated region. Biochem J (2004) 0.90
CTCF and BORIS regulate Rb2/p130 gene transcription: a novel mechanism and a new paradigm for understanding the biology of lung cancer. Mol Cancer Res (2011) 0.89
Exploiting our knowledge of NF-kappaB signaling for the treatment of mammary cancer. J Mammary Gland Biol Neoplasia (2006) 0.88
Dual association by TFAP2A during activation of the p21cip/CDKN1A promoter. Cell Cycle (2010) 0.86
Alternative TFAP2A isoforms have distinct activities in breast cancer. Breast Cancer Res (2011) 0.85
Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancer. Mol Endocrinol (2012) 0.85
Characterization of the human activator protein-2gamma (AP-2gamma) gene: control of expression by Sp1/Sp3 in breast tumour cells. Biochem J (2003) 0.83
Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens. Clin Cancer Res (2004) 0.81
Insulin-like growth factor-binding protein-5 enters vesicular structures but not the nucleus. Traffic (2007) 0.81
Competition on nitrocellulose-immobilized antibody arrays: from bacterial protein binding assay to protein profiling in breast cancer cells. Mol Cell Proteomics (2005) 0.78
Functional analysis of a breast cancer-associated FGFR2 single nucleotide polymorphism using zinc finger mediated genome editing. PLoS One (2013) 0.76
A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer. J Clin Invest (2017) 0.75